Archive
1250 articles, sorted by publication time.
Compared with the continued decline in the placebo group, the annualized change in kidney function among patients treated with sibeprenlimab was close to zero. This result will serve as key evidence for converting the US accelerated approval to traditional approval, although full analyses and longer-term clinical outcomes remain to be confirmed.
The global SAFFRON trial showed that savolitinib plus osimertinib was superior to platinum-based chemotherapy, providing a chemotherapy-free option after MET-driven resistance emerges in EGFR-mutated lung cancer; however, the full magnitude of benefit and safety data have not yet been disclosed.
From the recommendation to revoke authorization in June to the final decision, Tavneos has now been listed by the EU as a medicine whose authorization is no longer valid. At the heart of the controversy is not merely an analytical error, but the reassessment of patient data after unblinding, which pushed results that had originally failed to demonstrate superiority past the threshold for statistical significance.
By connecting artificial proteins capable of capturing specific drug molecules to an electrochemical reader, a Korean research and development project is attempting to shorten urine screening to mere seconds; however, currently available public data remain insufficient to assess its accuracy and reliability in the field.
Prader-Willi syndrome experts are urging clinicians to watch for more than 100 serious adverse events, including edema and cardiopulmonary complications. Existing reports cannot prove that the drug caused the deaths, but they make post-marketing surveillance and risk identification more urgent.
The iberdomide triplet regimen produced deep responses in four in ten patients, opening the door to the market for CELMoD protein-degrading drugs; however, the risks of infection and low blood cell counts were significant, and whether it can delay disease progression remains to be confirmed.
The all-cash acquisition will bring six sites across Europe, the United States, and India into Samsung’s global network, while making peptide manufacturing demand driven by the GLP-1 boom a new battleground for major biologics contract manufacturers.
An experimental antibody targeting a brain receptor involved in temperature regulation reduced the frequency and severity of vasomotor symptoms in a randomized, placebo-controlled trial; however, the findings remain company-reported topline results, and full efficacy and safety data have yet to be released.
Deep Origin combined machine learning with physics-based computation to select inhibitors of IRAK4, CD73, factor XIa, and IL-17A from approximately 80 billion virtual molecules; wet-lab hit rates were notable, but potency thresholds, reproducibility, and drug-like properties still require independent validation.
After 24 patients with idiopathic pulmonary fibrosis received 14 days of treatment, no severe treatment-emergent adverse events occurred, and lung samples showed changes in antifibrotic biomarkers; however, this small trial cannot yet demonstrate improvement in patients’ lung function or disease course.
A dual-target ADC already in a Phase 3 trial, together with a preclinical estrogen receptor degrader, will test whether Pathos can advance AI from an asset-screening tool into a verifiable system for trial design and patient stratification.
Research teams used priming immunizations followed by sequential boosters to progressively train B cells, enabling macaques to produce antibodies capable of targeting multiple HIV strains; this long-standing challenge has, for the first time, yielded consistent preclinical progress across multiple antibody pathways.